French biopharmaceutical firm Sanofi has signed a definitive agreement to purchase all outstanding shares of US-based biotechnology company Bioverativ for approximately $11.6bn.

In line with Sanofi’s 2020 Roadmap, the acquisition is expected to support its specialist care portfolio, provide platform for boosting position in rare blood disorders segment and enhance its sustainable revenue and earnings.

With a focus on the development of haemophilia treatments, Bioverativ currently markets Eloctate and Alprolix for haemophilia A and B in the US, Japan, Canada, Australia and the European Union (EU).

In addition, the company’s pipeline includes early stage research programmes and partnerships in haemophilia, as well as other rare blood disorders such as sickle cell disease and beta thalassemia.

“Together, we have a great opportunity to bring innovative medicines to patients worldwide.”

The deal will enable Sanofi to utilise Bioverativ’s clinical expertise and existing commercial footprint to advance its investigational RNA interference (RNAi) therapeutic called fitusiran for the treatment of haemophilia A and B, with or without inhibitors.

In turn, Sanofi’s research and development (R&D) organisation and commercialisation expertise are set to support Bioverativ in accelerating therapies to the market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Sanofi CEO Olivier Brandicourt said: “Together, we have a great opportunity to bring innovative medicines to patients worldwide, building on Bioverativ’s success in driving new standards of care with its extended half-life factor replacement therapies.

“Combined, we will continue to leverage our scientific know-how, disciplined focus and development expertise that best position us to drive value for our shareholders and create breakthrough treatments for patients.”

The transaction is subject to the satisfaction or waiver of customary closing conditions and is expected to close within three months.